Navigation Links
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
Date:8/24/2011

d potentially other biomarkers, in the future.  OncoCEE-BR™ is the only commercially available CTC test that combines enumeration and cytogenetic characterization.

Ron Andrews, CEO of Clarient, said, "Establishing the ability to perform molecular characterization of peripheral cancer cells from a blood sample takes us one step closer to making cancer a chronic disease.  Biocept's OncoCEE™ platform supports our mission of personalized medicine and care for cancer patients."

Biocept's OncoCEE-BR™ test is expected to have application in several clinical settings, including:

  • At the time of recurrence, and especially in cases where a biopsy may be difficult to obtain, to determine if the patient's HER2 status has changed from the original diagnosis or surgery.
  • Confirmation of HER2 status at the time of original diagnosis or surgery, where tumor tissue analysis was negative for HER2 amplification.  Biocept has demonstrated detection of HER2-amplified CTCs in patients with HER2 negative primary tumors, a finding reported by other groups in the scientific literature.  This suggests that the pathologist may have examined a part of the tumor that was not HER2 amplified for a variety of reasons including tumor heterogeneity, and that treatment with HER2-targeted agents may be justified.  This could be a life-changing event for a breast cancer patient.

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is an advanced diagnostic CLIA-certified laboratory services company specializing in the capture, detection, enumeration and molecular analysis of circulating tumor cells (CTCs). Biocept is dedicated to positively impacting the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes innovative and proprietary technologies to deliver clinically relevant an
'/>"/>

SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
5. Biocept, Inc. Announces New CFO
6. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BRâ„¢ Utilizing Circulating Tumor Cells (CTCs)
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
10. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
11. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Global biostimulants ... 2019 growing at an estimated CAGR of 12.5%. ... healthy food products with least ecological impacts, farmers ... fertilizers to boost crop yield more effectively & ... that can improve the return on investments. , ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
(Date:11/26/2014)... 2014  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... for the detection of foodborne pathogens, today announced that ... 26 th Annual Healthcare Conference on December 2, 2014 ... New York Palace in New York, NY ... the Company, its operations, strategies and prospects may be discussed. ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... US to incorporate partially absorbable mesh for use in ... improve healing and patient comfort , ... & Urology, a division of Ethicon, Inc., a Johnson ... Pelvic Floor Repair System is now available in the ...
... Ltd., a,privately-held drug development company with its headquarters ... new Phase IIa clinical testing of,ProtoCure(TM) emulsion cream, ... vehicle-controlled study is designed to,evaluate the tolerability, pharmacokinetics, ... of 18 subjects with mild to moderate plaque ...
... March 12 Helix BioPharma Corp. (TSX, FSE: "HBP") ... been declared effective by the U.S. Securities and Exchange ... the SEC pursuant to Section 12(g) of the Securities ... shares in the United States allows its shares to ...
Cached Biology Technology:GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System Launched in US for Use in Pelvic Organ Prolapse Surgery 2GYNECARE PROLIFT+M(TM) Pelvic Floor Repair System Launched in US for Use in Pelvic Organ Prolapse Surgery 3BioCis Pharma Starts Phase IIa Trial in Psoriasis 2Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC 2Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC 3
(Date:11/7/2014)...  In conjunction with the Glendale ... Foundation of the Verdugos has announced the " GLENDALE ... $250,000 initiative to keep the Verdugo Regional Crime Lab operational ... months of existence, the Lab has processed more than 400 ... enforcement. "Because our number one priority is the ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... Crop growth, drinking water and recreational water sports could ... patterns over the coming years prove true, according to ... of Soils . Scientists from Biotechnology and Biological ... for the first time that the rate at which ...
... the Frances and Joseph Weinberg Unit for ALS ... Thomas Jefferson University was recently awarded a Margaret ... drug therapies that showed promise in Amyotrophic Lateral ... human clinical trials. Dr. Pasinelli and her ...
... lead an international initiative to develop standards for sharing ... Internet. Dr Kerry Taylor and Amit Parashar ... Wide Web Consortium,s (W3C) Semantic Sensor Network incubator group. ... different types of sensing devices, and a new standard ...
Cached Biology News:Changing climate will lead to devastating loss of phosphorus from soil 2Jefferson researcher awarded Landenberger Foundation grant for ALS research 2
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
... need to perform time consuming and inaccurate comparison ... any found variants of the sample when compared ... our mutation electropherogram as a sharp peak. ... mode is over 99%, with sensitivity to greater ...
Biology Products: